Nucor earnings beat by $0.08, revenue fell short of estimates
BOSTON - Ginkgo Bioworks (NYSE:DNA), a biotechnology company with a robust balance sheet showing a current ratio of 4.88x, announced on Thursday the introduction of a new high-throughput ADME profiling service aimed at accelerating small molecule drug discovery. According to InvestingPro data, the company maintains strong liquidity with cash reserves exceeding its debt obligations.
The service, offered through Ginkgo Datapoints, leverages the company’s proprietary RAC automation to provide absorption, distribution, metabolism, and excretion profiling at competitive prices. According to the company’s statement, the service will match or beat pricing from international vendors while performing all work within the United States. This expansion comes as the company reports revenue of $237.4 million in the last twelve months, with a notable revenue growth rate of approximately 14%.
The ADME profiling service features automated workflows, rapid turnaround times, and datasets formatted for machine learning applications. The company states the service is designed to help researchers prioritize drug candidates earlier in the development process.
"We will price match any ADME service quote you get, though we hope to beat them on per-compound pricing out of the gate anyway," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks, in the press release.
The company indicates the new offering is part of its broader platform of cell programming and biosecurity services. Ginkgo Bioworks claims its automation capabilities enable it to deliver structured data at scale for use in artificial intelligence models.
Ginkgo Bioworks, which went public in 2021, has been expanding its portfolio of services for the pharmaceutical and biotechnology industries. This latest offering represents the company’s continued focus on laboratory automation and data generation for drug discovery applications.
The announcement comes as pharmaceutical companies increasingly seek cost-effective methods to accelerate their drug development pipelines while maintaining quality standards. While the stock has experienced a challenging period, declining about 11% over the past week, InvestingPro analysis suggests the company is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which provides detailed analysis of this and 1,400+ other US stocks.
In other recent news, Ginkgo Bioworks has reported a significant rise in its Q1 2025 revenue, particularly in its cell engineering division, which saw a 37% year-over-year increase, reaching $38 million. The company continues to focus on cost reduction and strategic expansion, aiming to achieve adjusted EBITDA breakeven by the end of 2026. Ginkgo Bioworks has also renewed its collaboration with Twist Bioscience through a new three-year, $15 million contract, allowing Ginkgo to continue ordering DNA products without minimum purchase requirements. Additionally, a new collaboration with Hugging Face was announced, aiming to enhance AI drug development by providing access to high-quality biological datasets. In a strategic move, Ginkgo Bioworks has appointed Steven Coen as the new CFO, following the resignation of Mark Dmytruk, effective May 2025. Analysts from BTIG and Bank of America have noted these developments, with BTIG’s Mark Massaro highlighting the potential for new revenue-generating programs. The company’s ongoing efforts in synthetic biology and partnerships continue to position it as a key player in the biotech industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.